Reply to Siddiqui et al., Godbout et al., and Chang and Mao
Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, Gilles Devouassoux, Andréanne Côté, Daniel J Jackson, David J Jackson, Michael E Wechsler, Peter Howarth, Ian D Pavord, all authors of ‘Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, dou · 2026
Read Reply to Siddiqui et al., Godbout et al., and Chang and Mao by Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, Gilles Devouassoux, Andréanne Côté, Daniel J Jackson, David J Jackson, Michael E Wechsler, Peter Howarth, Ian D Pavord, all authors of ‘Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, dou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13519336.txt.
Description
Geoffrey Chupp and ten co-authors reply to three sets of critics of their trial of a twice-yearly asthma injection. Their NIMBLE study asked whether patients well controlled on monthly biologics could switch to depemokimab, an ultra-long-acting drug given twice a year, without losing control. The trial's formal noninferiority test was not met, and letters questioned the authors' claim that switching looks safe.
The reply leans on absolute numbers. Attack rates were low on both arms; the average difference, 0.08 attacks per year, amounts to about one extra attack every twelve and a half years. Nearly everyone avoided attacks needing hospital care. The authors concede the gap was driven by patients switching from one particular comparator drug, where the absolute cost was still about one extra attack per five years. They note the journal's editorialists shared their reading: the difference is real but not clinically meaningful.
Catalog record
| CREATOR | Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, Gilles Devouassoux, Andréanne Côté, Daniel J Jackson, David J Jackson, Michael E Wechsler, Peter Howarth, Ian D Pavord, all authors of ‘Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, dou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |